

1 **Sex disparities in in-hospital outcomes after percutaneous coronary intervention**  
2 **(PCI) in patients with acute myocardial infarction and a history of coronary**  
3 **artery bypass grafting (CABG): A nationwide inpatient sample-matched analysis**  
4 **(2016–2019)**

5

6 **Short title:** Sex disparities after PCI with acute myocardial infarction and a history of  
7 CABG

8

9 Rui Yan<sup>1,4</sup>, Xueping Ma<sup>1,2,3</sup>, Bo Shi<sup>1,4</sup>, Congyan Ye<sup>1,4</sup>, Shizhe Fu<sup>1,4</sup>, Kairu Wang<sup>1,4</sup>,  
10 Haohong Qi<sup>1,4</sup>, Mingzhi Cui<sup>1,4</sup>, Ru Yan<sup>1,2,3\*</sup>, Shaobin Jia<sup>1,2,3\*</sup>, Guangzhi Cong<sup>1,2,3\*</sup>

11

12 <sup>1</sup>Institute of Medical Sciences, General Hospital of Ningxia Medical University,  
13 Yinchuan, Ningxia, China

14 <sup>2</sup>Institute of Cardiovascular Medicine, General Hospital of Ningxia Medical University,  
15 Ningxia, China

16 <sup>3</sup>Department of Cardiology, General Hospital of Ningxia Medical University, Ningxia  
17 Medical University, Ningxia, China

18 <sup>4</sup>School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia, China

19

20 \*Corresponding author

21 Email: [yanru208@gmail.com](mailto:yanru208@gmail.com) (RY)

22 [jsbxn@163.com](mailto:jsbxn@163.com) (SJ)

23 [schatz1898@gmail.com](mailto:schatz1898@gmail.com) (GC)

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 26 **Abstract**

### 27 **Background**

28 The role of sex disparities in in-hospital outcomes after percutaneous coronary  
29 intervention (PCI) for acute myocardial infarction (AMI) in patients with a history of  
30 coronary artery bypass grafting (CABG) remains underexplored. This study aimed to  
31 identify sex disparities in in-hospital outcomes after PCI in patients with AMI and a  
32 history of CABG.

### 33 **Methods**

34 Using the National Inpatient Sample database, we identified patients hospitalized for  
35 AMI with a history of CABG who underwent PCI between 2016 and 2019. The primary  
36 outcome was in--hospital mortality, and the secondary outcomes were the length of  
37 hospital stay and hospitalization costs. 1:1 propensity score matching was used to  
38 minimize standardized mean differences of baseline variables and compare in--hospital  
39 outcomes.

### 40 **Results**

41 In total, 75,185 weighted hospitalizations of patients who underwent PCI were  
42 identified, with 25.2% being female patients. Compared with male patients, female  
43 patients exhibited elevated risks of in-hospital mortality (3.72% vs. 2.85%,  $p = 0.0095$ ),  
44 longer length of stay (4.64 days vs. 3.96 days,  $p < 0.001$ ), and higher hospitalization  
45 costs (\$112,594.43 vs. \$107,020.54,  $p = 0.0019$ ). After propensity score matching,  
46 female patients had higher in-hospital mortality rates than male patients (3.81% vs.  
47 2.89%,  $p = 0.028$ ). Multivariable logistic regression (adjusted odds ratio [aOR]: 1.48;  
48 95% confidence interval [CI]: 1.14–1.92) and propensity score matching (aOR: 1.34;

49 95% CI: 1.03–1.73) showed a consistently higher risk of in-hospital mortality among  
50 female patients than among male patients. Female patients aged >60 years were more  
51 vulnerable to in-hospital mortality than were their male counterparts (3.06% vs. 4.15%,  
52  $p = 0.0003$ , aOR: 1.55; 95% CI: 1.18–2.04).

### 53 **Conclusions**

54 Female patients who underwent PCI for AMI with a history of CABG had a higher in-  
55 hospital mortality rate, which was particularly evident among older patients aged >60  
56 years. Therefore, sex- and age-specific investigations and interventions are required to  
57 reduce disparities within this high-risk population.

58

## 59 **Introduction**

60           Coronary artery bypass grafting (CABG) is the most commonly performed  
61 cardiac surgical procedure in adults [1] . However, despite advances in pharmacological  
62 and surgical techniques, saphenous vein graft (SVG) failure rates remain significant [2,  
63 3]. Furthermore, the development of atherosclerosis, thrombosis, and calcification in  
64 native coronary arteries is accentuated by bypass grafting [4, 5]. Consequently, patients  
65 with a history of CABG remain at risk for recurrent ischemic episodes in the months  
66 and years after surgery. This risk is primarily attributed to SVG occlusion and the  
67 progression of native coronary artery disease [6, 7]. Moreover, these patients frequently  
68 require additional revascularization because they experience recurring angina  
69 symptoms or present with acute coronary syndrome [8, 9]. The technique and strategy  
70 of further revascularization for this unique population remain challenging issues in  
71 therapeutic interventions for coronary heart disease (CAD). In these patients, simple  
72 pharmacological therapy adjustments frequently fail to control myocardial ischemia.  
73 Due to anatomical alterations, tissue adhesions, and the source of the bridging arteries,  
74 secondary thoracotomies for repeat CABG are not often recommended. Therefore, in  
75 patients with a susceptible anatomy, percutaneous coronary intervention (PCI) is the  
76 preferred revascularization strategy [10-12].

77           Female patients were more likely to undergo urgent CABG, but they still have a  
78 higher risk of post-procedural complications [13]. Previous studies have shown that the  
79 incidence of recurrent MI in female patients is higher than that in male patients after  
80 CABG surgery. Consequently, female patients often require further revascularization,  
81 such as PCI [14-16]. The female sex is seen as a risk factor for negative outcomes after  
82 PCI [17]. Although this disparity has repeatedly drawn attention, it has primarily been

83 attributed to variations in risk factor profiles between men and women, because it is  
84 diminished or eliminated in a multivariable analysis that controls for baseline  
85 confounders [18, 19]. Currently, no existing report in the literature has compared sex  
86 discrepancies in in-hospital outcomes after PCI among patients with acute myocardial  
87 infarction (AMI) who have a history of CABG. Consequently, debate persists owing to  
88 a lack of evidence. Thus, further research is required to elucidate sex differences in in-  
89 hospital outcomes following PCI in this patient population.

90 This study aimed to identify sex disparities in in-hospital outcomes after PCI in  
91 patients with AMI who have a history of CABG, using a nationally representative  
92 cohort. The hypothesis posited that the in-hospital mortality rate among female patients  
93 would be higher than that among male patients.

94

## 95 **Materials and methods**

### 96 **Data source**

97 This study utilized the National (Nationwide) Inpatient Sample (NIS), which is  
98 the largest all-payer database of hospital inpatient stays in the United States. The NIS  
99 is a component of the Healthcare Quality and Utilization Project (HCUP), sponsored  
100 by the Agency for Healthcare Research and Quality. It provides discharge information  
101 from a 20% stratified sample of community hospitals [20]. The NIS includes  
102 approximately 7 million unweighted records and 35 million weighted hospital  
103 encounters annually. National estimates can be measured using weighted data. The  
104 information provided for each discharge includes patient demographics, primary payer  
105 status, socioeconomic status, hospital features, primary diagnosis, up to 24 secondary  
106 diagnoses, and procedural diagnoses. The HCUP-NIS does not record information

107 about specific individual patients; rather, it records all data pertaining to a particular  
108 admission. Because the data within this database is de-identified and accessible to the  
109 public, the requirement for informed consent was waived. This study was approved by  
110 the Institutional Review Board of Ningxia Medical University and complied with the  
111 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)  
112 reporting guidelines [21].

113

## 114 **Study design and population**

115 Between January 1, 2016, and December 31, 2019, all hospitalizations of adults  
116 aged  $\geq 18$  years with a primary discharge diagnosis of AMI and a history of CABG,  
117 along with a procedural diagnosis of PCI, were included. These hospitalizations were  
118 stratified by sex. The International Classification of Diseases-10 Clinical Modification  
119 (ICD-10) and Clinical Classification Software codes were used to identify the clinical  
120 outcomes, procedures, and patient comorbidities (S1 Table). The 31 AHRQ Elixhauser  
121 comorbidity assessments currently in use were used to identify additional comorbidities  
122 [22] (S2 Table). To consider any variations at the hospital level, hospital-related  
123 variables, such as hospital bed size, region, and location/teaching status, were studied.  
124 The exclusion criteria were as follows: (1) receipt of CABG during the index admission  
125 ( $n = 97$ ), (2) history of prior PCI between 2016 and 2019 ( $n = 7,759$ ), (3) age  $< 18$  years  
126 ( $n = 1$ ), and (4) missing demographic data ( $n = 1089$ ) (Fig 1).

127 **Fig 1. Flowchart of patient selection.** CABG, coronary artery bypass grafting; PCI,  
128 percutaneous coronary intervention; AMI, acute myocardial infarction

129

## 130 **Outcomes**

131 The primary outcome of interest was in-hospital mortality. The secondary  
132 outcomes were the length of hospital stay, hospitalization costs, and difference in in-  
133 hospital mortality between male and female hospitalized patients according to age.

134

## 135 **Statistical analysis**

136 All variables are presented as weighted national estimates in accordance with  
137 HCUP-NIS guidance [23]. This was performed in accordance with the survey analysis  
138 strategy, using HOSP\_NIS as a clustering variable and NIS\_STRATUM to account for  
139 the different strata in the NIS design, as suggested by the Agency for Healthcare  
140 Research and Quality Methods series. For continuous variables, data are presented as  
141 survey-weighted mean (95% confidence intervals [CI]), and the p-value was calculated  
142 using survey-weighted linear regression. For categorical variables, data are reported as  
143 survey-weighted percentage (95% CI), and the *P*-value was calculated using the survey-  
144 weighted chi-square test.

145 Logistic regression models were used to assess the relationship between sex and  
146 in-hospital mortality. The adjusted OR (aOR) and 95% CI were computed after  
147 applying the multivariate-adjusted models. These confounders were selected based on  
148 their connections with in-hospital mortality, a change-in-effect estimate exceeding 10%,  
149 or a regression coefficient p-value of <0.1 with respect to the relationship between sex  
150 and in-hospital mortality [24]. Given the nonrandomized nature of the study design, 1:1  
151 propensity score matching was used to match male and female patients to assess the  
152 impact of sex on outcomes and mitigate confounding and selection biases via  
153 multivariable logistic regression. Matching variables are presented in S3 Table, with a  
154 matching tolerance set at 0.05. Standardized mean differences for all baseline variables  
155 were calculated to assess the balance of baseline characteristics before and after

156 matching. A standardized mean difference  $<0.10$  was regarded as a good balance of the  
157 baseline variable. The relationship between age and in-hospital mortality among male  
158 and female patients was explored using smooth curve fitting and subgroup analysis.

159 The R statistical software package (<http://www.R-project.org>; The R Foundation)  
160 and EmpowerStats (<http://www.empowerstats.com>; X&Y Solutions, Inc., Boston, MA,  
161 USA) were utilized for all analyses. Statistical significance was set at  $p < 0.05$  (two-  
162 sided).

163

## 164 **Results**

### 165 **Patient characteristics**

166 We identified 15,060 unweighted patients who underwent PCI for AMI with prior  
167 CABG in the NIS database between January 1, 2016, and December 31, 2019. This  
168 patient population comprised 11,261 (74.77%) and 3,799 (25.23%) male and female  
169 patients, respectively. After applying discharge weight, this represented 56,225 and  
170 18,960 male and female patients, respectively. Compared with male patients, female  
171 patients were more likely to be Black, have a lower socioeconomic status, and have  
172 Medicare/Medicaid as their primary payer (all  $p < 0.001$ ). A higher prevalence of  
173 obesity, diabetes, hypothyroidism, chronic pulmonary disease, valvular disease,  
174 depression, and fluid and electrolyte disorders (all  $p < 0.001$ ) was observed among  
175 female patients than among male patients. Smoking, alcohol abuse, prior AMI,  
176 dyslipidemia, congestive heart failure, hypertension, ventricular fibrillation, and  
177 intracardiac thrombus were more common among male patients (all  $p < 0.05$ ). Overall,  
178 female patients had a higher burden of Elixhauser comorbidities (comorbidity index  $>4$ ,  
179 33.10% vs. 27.11%,  $p < 0.001$ ) (Table 1). PSM well balanced the baseline variables,



180 with almost all the standardized mean differences <0.1 (S4 Table).

181

182 **Table 1. Baseline characteristics of female versus male patients in the cohort**

183 **before propensity score matching (weighted)**

<b>Variables*</b>	<b>Male N = 56,225</b>	<b>Female N = 18,960</b>	<b>p-value</b>
<b>Age, years</b>	70.38 (70.01, 70.76)	70.40 (70.03, 70.78)	0.949
<b>Race</b>			<0.001
<b>White</b>	83.41 (82.35, 84.41)	74.02 (72.03, 75.92)	
<b>Black</b>	5.90 (5.36, 6.50)	13.19 (11.64, 14.90)	
<b>Hispanic</b>	6.36 (5.75, 7.03)	8.18 (6.78, 9.83)	
<b>Others</b>	4.33 (3.86, 4.85)	4.61 (3.92, 5.43)	
<b>Primary pay</b>			<0.001
<b>Medicare/Medicaid</b>	75.23 (74.03, 76.40)	82.78 (81.35, 84.12)	
<b>Private insurance</b>	18.38 (17.36, 19.45)	13.08 (11.91, 14.35)	
<b>Self-pay</b>	2.61 (1.85, 3.65)	2.56 (2.09, 3.13)	
<b>No charge/others</b>	3.78 (3.25, 4.40)	1.58 (1.23, 2.04)	
<b>Median household income</b>			<0.001
<b>0–25th</b>	29.18 (27.23, 31.20)	36.21 (34.02, 38.46)	
<b>26–50th</b>	29.17 (27.67, 30.71)	28.93 (27.29, 30.63)	
<b>51–75th</b>	24.49 (22.51, 26.59)	20.83 (19.33, 22.42)	
<b>76–100th</b>	17.16 (15.57, 18.88)	14.03 (12.37, 15.87)	
<b>Hospital region</b>			<0.001
<b>Northeast</b>	20.79 (16.54, 25.80)	17.06 (14.11, 20.48)	

<b>Midwest</b>	23.46 (21.85, 25.15)	24.53 (22.87, 26.26)	
<b>South</b>	45.66 (42.81, 48.55)	49.02 (46.57, 51.48)	
<b>West</b>	10.08 (9.27, 10.96)	9.39 (8.42, 10.45)	
<b>Teaching status of the hospital</b>			0.228
<b>Rural hospital</b>	6.06 (5.47, 6.72)	6.86 (5.99, 7.84)	
<b>Urban non-teaching</b>	20.57 (19.07, 22.15)	19.86 (18.39, 21.42)	
<b>Urban teaching</b>	73.37 (71.47, 75.18)	73.29 (71.47, 75.03)	
<b>Bed size of the hospital</b>			0.271
<b>Small</b>	15.20 (13.39, 17.20)	15.69 (14.05, 17.49)	
<b>Medium</b>	31.17 (28.53, 33.94)	29.30 (27.47, 31.20)	
<b>Large</b>	53.63 (50.59, 56.65)	55.01 (52.62, 57.37)	
<b>Comorbidities</b>			
<b>Known CAD</b>	9.27 (8.44, 10.16)	8.23 (7.32, 9.24)	0.076
<b>Family history of CAD</b>	12.09 (11.12, 13.15)	13.21 (11.40, 15.26)	0.375
<b>Prior MI</b>	28.95 (27.62, 30.31)	24.89 (23.26, 26.61)	<0.001
<b>Prior CVA</b>	10.32 (9.21, 11.56)	12.53 (11.04, 14.19)	0.009
<b>Prior PPM or ICD</b>	4.88 (4.31, 5.53)	4.48 (3.85, 5.22)	0.365
<b>Smoking</b>	52.72 (50.65, 54.77)	42.59 (40.85, 44.35)	<0.001
<b>Obesity</b>	16.92 (15.99, 17.90)	19.78 (18.35, 21.28)	<0.001
<b>Alcohol abuse</b>	2.29 (1.79, 2.93)	0.37 (0.22, 0.62)	<0.001
<b>Drug abuse</b>	1.61 (1.37, 1.89)	1.58 (1.22, 2.05)	0.910
<b>Dyslipidemia</b>	82.77 (81.90, 83.62)	80.93 (79.10, 82.64)	0.039
<b>Carotid artery disease</b>	3.01 (2.66, 3.41)	3.56 (3.00, 4.23)	0.104

<b>Atrial fibrillation</b>	19.88 (17.85, 22.09)	17.75 (16.41, 19.17)	0.138
<b>Ventricular fibrillation</b>	2.53 (2.22, 2.87)	1.87 (1.48, 2.37)	0.023
<b>Congestive heart failure</b>	35.49 (33.95, 37.06)	32.36 (30.75, 34.01)	0.008
<b>Deficiency anemia</b>	2.30 (2.01, 2.63)	4.01 (3.41, 4.70)	<0.001
<b>Chronic blood loss anemia</b>	0.35 (0.25, 0.48)	0.63 (0.42, 0.94)	0.019
<b>Coagulopathy</b>	5.35 (4.85, 5.91)	4.88 (3.53, 6.71)	0.626
<b>Hypertension</b>	60.16 (58.42, 61.87)	56.33 (54.52, 58.12)	<0.001
<b>Diabetes</b>	51.04 (49.59, 52.49)	59.84 (58.14, 61.51)	<0.001
<b>Depression</b>	7.65 (6.91, 8.46)	13.87 (12.70, 15.13)	<0.001
<b>Chronic pulmonary disease</b>	23.26 (22.42, 24.13)	30.70 (29.09, 32.35)	<0.001
<b>Pulmonary circulation disorders</b>	0.27 (0.19, 0.38)	0.29 (0.16, 0.52)	0.812
<b>Intracardiac thrombus</b>	0.38 (0.28, 0.52)	0.13 (0.05, 0.32)	0.018
<b>Hypothyroidism</b>	10.20 (9.19, 11.31)	21.31 (19.76, 22.94)	<0.001
<b>Liver disease</b>	2.88 (2.31, 3.59)	3.40 (2.28, 5.05)	0.485
<b>Rheumatoid arthritis, collagen vascular diseases</b>	2.45 (1.46, 4.08)	4.17 (3.57, 4.86)	0.062
<b>Cancer</b>	1.87 (1.43, 2.43)	1.27 (0.96, 1.68)	0.044
<b>Fluid and electrolyte disorder</b>	18.46 (17.12, 19.88)	24.00 (22.41, 25.66)	<0.001
<b>Stroke</b>	1.04 (0.86, 1.26)	1.45 (1.11, 1.89)	0.041
<b>Other neurological</b>	5.74 (5.08, 6.49)	6.22 (5.47, 7.07)	0.347

<b>disorders</b>			
<b>Peripheral vascular disease</b>	20.39 (18.79, 22.09)	19.22 (17.83, 20.70)	0.204
<b>Chronic renal failure</b>	32.14 (30.93, 33.37)	32.57 (30.98, 34.20)	0.680
<b>Acute renal failure</b>	19.41 (18.02, 20.89)	20.97 (19.53, 22.48)	0.076
<b>Valvular disease</b>	16.67 (15.54, 17.85)	21.49 (19.93, 23.14)	<0.001
<b>Cardiogenic shock</b>	5.36 (4.71, 6.10)	5.46 (4.77, 6.25)	0.843
<b>Cardiac arrest</b>	2.47 (2.17, 2.82)	2.48 (2.02, 3.03)	0.982
<b>Elixhauser comorbidities</b>			<0.001
<b>0</b>	2.00 (1.73, 2.32)	1.16 (0.86, 1.56)	
<b>1–4</b>	70.89 (69.46, 72.29)	65.74 (64.11, 67.35)	
<b>&gt;4</b>	27.11 (25.73, 28.52)	33.10 (31.50, 34.73)	
<b>Vasopressor use</b>	1.04 (0.67, 1.61)	0.61 (0.40, 0.93)	0.080
<b>Coronary angiography</b>	76.33 (74.50, 78.06)	77.87 (74.72, 80.74)	0.209
<b>Invasive hemodynamic monitoring</b>	5.04 (4.44, 5.73)	4.64 (3.98, 5.40)	0.428
<b>MCS</b>	4.55 (4.10, 5.05)	4.59 (3.95, 5.33)	0.929

184 CAD, coronary artery disease; MI, myocardial infarction; CVA, cardiovascular  
 185 accident; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator;  
 186 MCS, mechanical circulatory support

187 \* Values are percentage or median (interquartile range).

188

## 189 Outcomes

190 During the hospital stay, in the overall cohort, female patients had a higher

191 prevalence of in-hospital mortality (3.72% vs. 2.85%,  $p = 0.009$ ), longer length of stay  
 192 (4.64 days vs. 3.96 days,  $p < 0.001$ ), and higher hospitalization costs (\$112,594.43 vs  
 193 \$107,020.54,  $p = 0.002$ ) than did male patients. After propensity score matching, female  
 194 patients had a higher in-hospital mortality rate and longer length of stay than did male  
 195 patients (3.81% vs. 2.89%,  $p = 0.028$  and  $4.61 \pm 4.76$  days vs.  $4.02 \pm 4.35$  days,  $p <$   
 196  $0.001$ , respectively), while the relationship between sex and hospitalization costs was  
 197 no longer significant ( $\$113,797.03 \pm 96,086.46$  vs.  $\$111,768.45 \pm 92,179.28$ ,  $p = 0.354$ )  
 198 (Tables 2 and 3). Multivariable logistic regression (aOR: 1.48; 95% CI: 1.14–1.92) and  
 199 propensity score matching (aOR: 1.34; 95% CI: 1.03–1.73) showed a consistently  
 200 higher risk of in-hospital mortality among female patients than among male patients  
 201 (Table 4).

202

203 **Table 2. Comparison of in-hospital outcomes between female and male patients in**  
 204 **the overall cohort**

	Male, N = 56225	Female, N = 18960	p-value
<b>In-hospital mortality (%)</b>	2.85 (2.52, 3.23)	3.72 (3.14, 4.39)	0.009
<b>Length of stay, days</b>	3.96 (3.85, 4.06)	4.64 (4.44, 4.84)	<0.001
<b>Total hospitalization costs, \$</b>	107020.54 (103859.25, 110181.83)	112594.43 (108917.49, 116271.37)	0.002

205 Values are percentage or median (interquartile range).

206

207 **Table 3. Comparison of in-hospital outcomes between female and male patients in**

208 **the matched cohort**

	<b>Male, N = 3700</b>	<b>Female, N = 3700</b>	<b>p-value</b>
<b>In-hospital mortality (%)</b>	2.89	3.81	0.028
<b>Length of stay, days</b>	4.02 ± 4.35	4.61 ± 4.76	<0.001
<b>Total hospitalization costs, \$</b>	111,768.45±92,179.28	113,797.03 ± 96,086.46	0.354

209 Values are percentage or mean ± SD

210 **Table 4. In-hospital mortality of multivariable logistic regression and**  
 211 **propensity-matched multivariate logistic regression**

	<b>aOR (95% CI)</b>	<b>p-value</b>
<b>Overall cohort</b>	1.48 (1.14, 1.92)	0.004
<b>Matched cohort</b>	1.34 (1.03, 1.73)	0.029

212 Note: aOR (95% CI) *P*-value

213 The model was adjusted for the following factors: age; race, primary pay, ZIP  
 214 income, hospital region, teaching status of the hospital, bed-size of the hospital,  
 215 smoking, dyslipidemia, family history of coronary artery disease, prior myocardial  
 216 infarction, atrial fibrillation, congestive heart failure, deficiency anemia, chronic blood  
 217 loss anemia, chronic pulmonary disease, coagulopathy, depression, diabetes mellitus;  
 218 hypertension, hypothyroidism, liver disease, fluid and electrolyte disorder, other  
 219 neurological disorders, pulmonary circulation disorders, chronic renal failure, valvular  
 220 disease, obesity, cardiogenic shock, stroke, ventricular fibrillation, cardiac arrest, acute  
 221 renal failure, coronary angiography, invasive hemodynamic monitoring, vasopressor

222 use, mechanical circulatory support.

223 aOR, adjusted odds ratio; CI, confidence interval

224

## 225 **Comparison of in-hospital mortality according to age**

226 Smooth curve fitting revealed an upward trend in in-hospital mortality in all age  
227 groups, with a larger increase occurring among patients aged >60 years. Subgroup  
228 analysis revealed that female patients aged >60 years were more vulnerable to in-  
229 hospital mortality than were their male counterparts (3.06% vs. 4.15%; aOR: 1.55; 95%  
230 CI: 1.18–2.04) (Table 5 and Fig 2).

231

232 **Table 5. Subgroup analysis of in-hospital mortality according to age**

	<b>Male</b>	<b>Female</b>	<b>aOR (95% CI)</b>	<b>p-value</b>
<b>Age ≤ 60 years</b>	40/2007 (1.99% )	12/692 (1.73%)	0.91 (0.36, 2.33)	0.848
<b>Age &gt; 60 years</b>	283/9254 (3.06%)	141/3107 (4.15%)	1.55 (1.18, 2.04)	0.002

233 aOR: adjusted odds ratio

234 The model was adjusted for the following factors: race; primary pay; ZIP income;  
235 hospital region; teaching status of the hospital; bed-size of the hospital; smoking;  
236 dyslipidemia; family history of coronary artery disease; prior myocardial infarction;  
237 atrial fibrillation; congestive heart failure; deficiency anemia; chronic blood loss  
238 anemia; chronic pulmonary disease; coagulopathy; depression; diabetes mellitus;  
239 hypertension; hypothyroidism; liver disease; fluid and electrolyte disorder; other  
240 neurological disorders; pulmonary circulation disorders; chronic renal failure; valvular

241 disease; obesity; cardiogenic shock; stroke; ventricular fibrillation; cardiac arrest; acute  
242 renal failure; coronary angiography; invasive hemodynamic monitoring; vasopressor  
243 use; mechanical circulatory support.

244 **Fig 2. Comparison of in-hospital mortality according to age.**

245

## 246 **Discussion**

247 In this study, we investigated sex disparities in the in-hospital outcomes of  
248 patients with AMI who underwent PCI and had a history of CABG. The main findings  
249 were as follows: (1) in both the overall and matched cohorts, female patients had a  
250 higher in-hospital mortality rate than did male patients and (2) female patients aged >60  
251 years were at greater risk of in-hospital mortality than were their male counterparts.

252

### 253 **Sex differences in in-hospital outcomes in patients who** 254 **underwent PCI for AMI and had a history of CABG**

255 Numerous reports have explored sex disparities in in-hospital outcomes following  
256 revascularization in patients with AMI [17, 18, 25]. However, data on sex differences  
257 in recurrent hospitalization and repeat revascularization are limited. Previous studies  
258 have shown that both SVG failure and the progression of native artery disease  
259 contribute to the need for repeat revascularization following CABG [26]. Compared  
260 with male patients, female patients were associated with higher rates of recurrent  
261 revascularization due to narrower native coronary arteries and bypass conduits, a higher  
262 tendency to spasm, and incomplete revascularization [15, 27-31]. Female patients often  
263 prefer receiving PCI over undergoing repeat CABG because of their smaller chest  
264 cavities and thinner and smaller arteries, which increase their vulnerability to



265 mechanical complications [32, 33]. Nevertheless, no existing study in the literature has  
266 explored sex differences in in-hospital outcomes after PCI in patients with a history of  
267 CABG. In our overall and matched cohorts, the risk of in-hospital mortality was higher  
268 in female patients than in male patients who underwent PCI.

269 Several possible explanations can be proffered for the increased risk of in-hospital  
270 mortality after PCI in female patients with a history of CABG. First, compared with  
271 male patients, female patients with AMI typically seek medical attention later following  
272 symptom onset; tend to experience longer delays even after reaching the emergency  
273 room, including longer triage and door-to-balloon times; and have lower rates of  
274 medical therapy that is guided by guidelines, which may be a factor in poorer outcomes  
275 [34, 35]. Other factors contributing to longer delays in seeking medical care among  
276 female patients, compared with male patients, include lack of knowledge, less  
277 aggressive treatment, fear, humiliation, and earlier incorrect diagnoses of chest  
278 discomfort by a medical professional [35-37]. Second, the higher in-hospital mortality  
279 rates among female patients may be partially attributed to their greater burden of  
280 comorbidities than that among male patients [38, 39]. Consistent with these  
281 observations, the current study revealed that female patients were more likely to have  
282 comorbidities, including diabetes, renal failure, hypothyroidism, chronic pulmonary  
283 disease, valvular disease, and fluid and electrolyte disorders. Even after adjusting for  
284 demographics, hospital characteristics, and comorbidities, female patients tended to  
285 have a higher in-hospital mortality rate than did their male counterparts. In some  
286 circumstances, these differences could be linked to pathophysiological variations. Third,  
287 anatomical and pathophysiological differences, such as smaller arterial diameters and  
288 worse hemodynamic states in female patients, can cause higher risks of bleeding  
289 problems and vascular injury [40, 41]. Additionally, left main lesions in female patients

290 are often ostial and do not require bifurcation stenting. However, they are more  
291 frequently severely calcific and necessitate the use of rotational atherectomy [42].  
292 Fourth, according to current recommendations, female patients receive less antiplatelet  
293 therapy, fewer statin prescriptions, and fewer referrals to cardiac rehabilitation [43].

294

## 295 **Sex differences in in-hospital mortality were more** 296 **pronounced among older patients**

297 Notably, this study found that female patients aged >60 years were at greater risk  
298 of in-hospital mortality than were their male counterparts. Anderson et al. analyzed  
299 outcomes in patients aged >65 years who underwent PCI and showed that female  
300 patients had a higher in-hospital mortality rate [44]. However, the study only included  
301 patients aged >65 years, whereas the current study enrolled patients of all age groups  
302 with a history of CABG. Several factors contribute to a higher in-hospital mortality rate  
303 among older female patients.

304 First, multiple studies have demonstrated that estrogen can reduce myocardial  
305 apoptosis, protect myocardial cells, and prevent plaque rupture. After menopause, when  
306 the preventive effects of estrogen subside, the risk of CAD in women increases  
307 significantly. Hence, female patients presenting with CAD tend to be older than their  
308 male counterparts, suffer multiple complications with aging, and have a higher in-  
309 hospital mortality rate [45, 46]. Notably, older female patients have significantly higher  
310 rates of cardiac hypertrophy, which is a risk factor for mortality [47]. Additionally, the  
311 incidence of cerebral hemorrhage and embolic strokes is higher among older female  
312 patients [48, 49]. Furthermore, age and female sex are two of the most important  
313 characteristics linked to cardiac rupture following myocardial infarction [50]. Second,

314 when compared with the transfemoral method, transradial PCI showed a reduced  
315 complication rate and a higher technical success rate in older patients [51]. Notably,  
316 older female patients tend to prefer femoral artery access [52]. Finally, older female  
317 patients with CAD undergoing PCI were frequently weak and malnourished, and these  
318 factors are strongly associated with increased all-cause mortality [53, 54]. Further  
319 investigation is required to examine the impact of sex and age on in-hospital mortality  
320 and repeat revascularization in patients with a history of CABG.

321

## 322 **Limitations**

323 This study has several limitations. First, although the use of ICD-10 codes has  
324 been validated for cardiovascular outcomes research, the NIS is an administrative  
325 dataset, which may contain coding errors [55]. Additionally, the NIS lacks clinical  
326 details, such as medication, biochemistry, and imaging data. Moreover, ICD-10  
327 diagnosis codes could not be used to determine the extent and severity of AMI. They  
328 also did not allow us to evaluate the quantity of revascularized vessels, extent of  
329 revascularization, quantity and type of stents, or the total length of the stents. In addition,  
330 no long-term follow-up data were available in the NIS dataset. Second, as with all  
331 retrospective studies, this study may have been subject to selection and observational  
332 biases. Third, due to the vague coding for coronary spasm or spontaneous coronary  
333 artery dissection, conditions more commonly found in young female patients presenting  
334 with AMI, they could not be determined in this cohort [56]. Finally, we could not assess  
335 the details of the progression of native coronary arteries and SVG failure after CABG.

336

## 337 **Strengths**

338           Despite these limitations, to the best of our knowledge, no study has examined sex  
339   disparities in patients with AMI and a history of CABG who undergo PCI. The large  
340   sample size provided ample statistical power to detect sex disparities in clinical  
341   outcomes among the patient groups studied. Furthermore, our data represent the best  
342   current evidence in the US population, considering that patients with a history of CABG  
343   are frequently excluded from or underrepresented in landmark PCI trials. In addition,  
344   multivariate analysis and propensity score matching were performed to minimize  
345   confounding and selection biases. Finally, the NIS contains information from more than  
346   7 million hospital stays annually, which can be applied to the entire American  
347   population.

348

## 349   **Conclusions**

350           The current study showed that female patients who underwent PCI for AMI with  
351   a history of CABG had a higher in-hospital mortality rate, which was more pronounced  
352   among older patients aged >60 years. Therefore, sex- and age-specific investigations  
353   and interventions are required to reduce disparities within this high-risk population.

## 354 **Acknowledgements**

355 We acknowledge the NIS (Nationwide Inpatient Sample) for providing the data.

356

## 357 **References**

358 1. McDermott KW, Freeman WJ, Elixhauser A. Overview of Operating Room  
359 Procedures During Inpatient Stays in U.S. Hospitals, 2014. Healthcare Cost and  
360 Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006.

361 2. Cao C, Ang SC, Wolak K, Peeceeyen S, Bannon P, Yan TD. A meta-analysis of  
362 randomized controlled trials on mid-term angiographic outcomes for radial artery  
363 versus saphenous vein in coronary artery bypass graft surgery. *Ann Cardiothorac Surg.*  
364 2013;2(4):401-7.

365 3. Xenogiannis I, Zenati M, Bhatt DL, Rao SV, Rodes-Cabau J, Goldman S, et al.  
366 Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment  
367 Strategies. *Circulation.* 2021;144(9):728-45.

368 4. Kwiecinski J, Tzolos E, Fletcher AJ, Nash J, Meah MN, Cadet S, et al. Bypass  
369 Grafting and Native Coronary Artery Disease Activity. *JACC Cardiovasc Imaging.*  
370 2022;15(5):875-87.

371 5. Pereg D, Fefer P, Samuel M, Wolff R, Czarnecki A, Deb S, et al. Native coronary  
372 artery patency after coronary artery bypass surgery. *JACC Cardiovasc Interv.*  
373 2014;7(7):761-7.

374 6. Beerkens FJ, Claessen BE, Mahan M, Gaudino MFL, Tam DY, Henriques JPS, et

- 375 al. Contemporary coronary artery bypass graft surgery and subsequent percutaneous  
376 revascularization. *Nat Rev Cardiol.* 2022;19(3):195-208.
- 377 7. Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, et  
378 al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. *J*  
379 *Am Coll Cardiol.* 2019;74(9):1177-86.
- 380 8. Rathod KS, Beirne AM, Bogle R, Firoozi S, Lim P, Hill J, et al. Prior Coronary  
381 Artery Bypass Graft Surgery and Outcome After Percutaneous Coronary Intervention:  
382 An Observational Study From the Pan-London Percutaneous Coronary Intervention  
383 Registry. *J Am Heart Assoc.* 2020;9(12):e014409.
- 384 9. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, et al.  
385 Secondary prevention after coronary artery bypass graft surgery: a scientific statement  
386 from the American Heart Association. *Circulation.* 2015;131(10):927-64.
- 387 10. Farag M, Gue YX, Brilakis ES, Egred M. Meta-analysis Comparing Outcomes of  
388 Percutaneous Coronary Intervention of Native Artery Versus Bypass Graft in Patients  
389 With Prior Coronary Artery Bypass Grafting. *Am J Cardiol.* 2021;140:47-54.
- 390 11. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et  
391 al. [2018 ESC/EACTS Guidelines on myocardial revascularization]. *Kardiol Pol.*  
392 2018;76(12):1585-664.
- 393 12. Faisaluddin M, Sattar Y, Manasrah N, Patel N, Taha A, Takla A, et al.  
394 Cardiovascular Outcomes of Redo-coronary Artery Bypass Graft Versus Percutaneous  
395 Coronary Intervention of Index Bypass Grafts Among Acute Coronary Syndrome:  
396 Regression Matched National Cohort Study. *Curr Probl Cardiol.* 2023;48(5):101580.

- 397 13. Gaudino M, Chadow D, Rahouma M, Soletti GJ, Sandner S, Perezgrovas-Olaria  
398 R, et al. Operative Outcomes of Women Undergoing Coronary Artery Bypass Surgery  
399 in the US, 2011 to 2020. *JAMA Surg.* 2023;158(5):494-502.
- 400 14. Nicolini F, Vezzani A, Fortuna D, Contini GA, Pacini D, Gabbieri D, et al. Gender  
401 differences in outcomes following isolated coronary artery bypass grafting: long-term  
402 results. *J Cardiothorac Surg.* 2016;11(1):144.
- 403 15. Gaudino M, Di Franco A, Alexander JH, Bakaeen F, Egorova N, Kurlansky P, et  
404 al. Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis  
405 of individual patient data. *Eur Heart J.* 2021;43(1):18-28.
- 406 16. Bradshaw PJ, Jamrozik K, Le M, Gilfillan I, Thompson PL. Mortality and recurrent  
407 cardiac events after coronary artery bypass graft: long term outcomes in a population  
408 study. *Heart.* 2002;88(5):488-94.
- 409 17. Epps KC, Holper EM, Selzer F, Vlachos HA, Gualano SK, Abbott JD, et al. Sex  
410 Differences in Outcomes Following Percutaneous Coronary Intervention According to  
411 Age. *Circ Cardiovasc Qual Outcomes.* 2016;9(2 Suppl 1):S16-25.
- 412 18. Duvernoy CS, Smith DE, Manohar P, Schaefer A, Kline-Rogers E, Share D, et al.  
413 Gender differences in adverse outcomes after contemporary percutaneous coronary  
414 intervention: an analysis from the Blue Cross Blue Shield of Michigan Cardiovascular  
415 Consortium (BMC2) percutaneous coronary intervention registry. *Am Heart J.*  
416 2010;159(4):677-83 e1.
- 417 19. Alfredsson J, Lindback J, Wallentin L, Swahn E. Similar outcome with an invasive  
418 strategy in men and women with non-ST-elevation acute coronary syndromes: from the

- 419 Swedish Web-System for Enhancement and Development of Evidence-Based Care in  
420 Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).  
421 Eur Heart J. 2011;32(24):3128-36.
- 422 20. Healthcare Cost And Utilization Project (HCUP). Introduction to the HCUP  
423 National Inpatient Sample (NIS) 2019 2021 [updated 16/09; cited 2022  
424 01/08/2022]. Available from: [https://www.hcup-](https://www.hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2019.pdf)  
425 [us.ahrq.gov/db/nation/nis/NISIntroduction2019.pdf](https://www.hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2019.pdf).
- 426 21. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock  
427 SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology  
428 (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
- 429 22. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use  
430 with administrative data. Med Care. 1998;36(1):8–27.
- 431 23. Khera R, Krumholz HM. With Great Power Comes Great Responsibility: Big Data  
432 Research From the National Inpatient Sample. Circ Cardiovasc Qual Outcomes.  
433 2017;10(7).
- 434 24. Jaddoe VW, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R. First  
435 trimester fetal growth restriction and cardiovascular risk factors in school age children:  
436 population based cohort study. BMJ. 2014;348:g14.
- 437 25. Bryce Robinson N, Naik A, Rahouma M, Morsi M, Wright D, Hameed I, et al. Sex  
438 differences in outcomes following coronary artery bypass grafting: a meta-analysis.  
439 Interact Cardiovasc Thorac Surg. 2021;33(6):841-7.
- 440 26. Fosbol EL, Zhao Y, Shahian DM, Grover FL, Edwards FH, Peterson ED. Repeat



- 441 coronary revascularization after coronary artery bypass surgery in older adults: the  
442 Society of Thoracic Surgeons' national experience, 1991-2007. *Circulation*.  
443 2013;127(16):1656-63.
- 444 27. Matyal R, Qureshi NQ, Mufarrih SH, Sharkey A, Bose R, Chu LM, et al. Update:  
445 Gender differences in CABG outcomes-Have we bridged the gap? *PLoS One*.  
446 2021;16(9):e0255170.
- 447 28. Guru V, Fremes SE, Austin PC, Blackstone EH, Tu JV. Gender differences in  
448 outcomes after hospital discharge from coronary artery bypass grafting. *Circulation*.  
449 2006;113(4):507-16.
- 450 29. Sheifer SE, Canos MR, Weinfurt KP, Arora UK, Mendelsohn FO, Gersh BJ, et al.  
451 Sex differences in coronary artery size assessed by intravascular ultrasound. *Am Heart*  
452 *J*. 2000;139(4):649-53.
- 453 30. Lawton JS, Barner HB, Bailey MS, Guthrie TJ, Moazami N, Pasque MK, et al.  
454 Radial artery grafts in women: utilization and results. *Ann Thorac Surg*.  
455 2005;80(2):559-63.
- 456 31. Kurlansky PA, Traad EA, Galbut DL, Singer S, Zucker M, Ebra G. Coronary  
457 bypass surgery in women: a long-term comparative study of quality of life after bilateral  
458 internal mammary artery grafting in men and women. *Ann Thorac Surg*.  
459 2002;74(5):1517-25.
- 460 32. Mohamed MO, Shoaib A, Gogas B, Patel T, Alraies MC, Velagapudi P, et al.  
461 Trends of repeat revascularization choice in patients with prior coronary artery bypass  
462 surgery. *Catheter Cardiovasc Interv*. 2021;98(3):470-80.

- 463 33. Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of  
464 revascularization method and long-term outcome of percutaneous coronary  
465 intervention or repeat coronary bypass surgery in patients with multivessel coronary  
466 disease and previous coronary bypass surgery. *Eur Heart J.* 2006;27(4):413-8.
- 467 34. Swaminathan RV, Wang TY, Kaltenbach LA, Kim LK, Minutello RM, Bergman  
468 G, et al. Nonsystem reasons for delay in door-to-balloon time and associated in-hospital  
469 mortality: a report from the National Cardiovascular Data Registry. *J Am Coll Cardiol.*  
470 2013;61(16):1688-95.
- 471 35. Bugiardini R, Ricci B, Cenko E, Vasiljevic Z, Kedev S, Davidovic G, et al. Delayed  
472 Care and Mortality Among Women and Men With Myocardial Infarction. *J Am Heart*  
473 *Assoc.* 2017;6(8).
- 474 36. Pagidipati NJ, Peterson ED. Acute coronary syndromes in women and men. *Nat*  
475 *Rev Cardiol.* 2016;13(8):471-80.
- 476 37. Moser DK, McKinley S, Dracup K, Chung ML. Gender differences in reasons  
477 patients delay in seeking treatment for acute myocardial infarction symptoms. *Patient*  
478 *Educ Couns.* 2005;56(1):45-54.
- 479 38. Kosmidou I, Leon MB, Zhang Y, Serruys PW, von Birgelen C, Smits PC, et al.  
480 Long-Term Outcomes in Women and Men Following Percutaneous Coronary  
481 Intervention. *J Am Coll Cardiol.* 2020;75(14):1631-40.
- 482 39. Sambola A, Del Blanco BG, Kunadian V, Vogel B, Chieffo A, Vidal M, et al. Sex-  
483 based Differences in Percutaneous Coronary Intervention Outcomes in Patients with  
484 Ischaemic Heart Disease. *Eur Cardiol.* 2023;18:e06.


- 485 40. O'Connor NJ, Morton JR, Birkmeyer JD, Olmstead EM, O'Connor GT. Effect of  
486 coronary artery diameter in patients undergoing coronary bypass surgery. Northern  
487 New England Cardiovascular Disease Study Group. *Circulation*. 1996;93(4):652-5.
- 488 41. Vakili BA, Kaplan RC, Brown DL. Sex-based differences in early mortality of  
489 patients undergoing primary angioplasty for first acute myocardial infarction.  
490 *Circulation*. 2001;104(25):3034-8.
- 491 42. Moroni F, Beneduce A, Giustino G, Briede I, Park SJ, Daemen J, et al. Sex  
492 Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery  
493 Bypass Graft for Left Main Disease: From the DELTA Registries. *J Am Heart Assoc*.  
494 2022;11(5):e022320.
- 495 43. Thakkar A, Agarwala A, Michos ED. Secondary Prevention of Cardiovascular  
496 Disease in Women: Closing the Gap. *Eur Cardiol*. 2021;16:e41.
- 497 44. Anderson ML, Peterson ED, Brennan JM, Rao SV, Dai D, Anstrom KJ, et al. Short-  
498 and long-term outcomes of coronary stenting in women versus men: results from the  
499 National Cardiovascular Data Registry Centers for Medicare & Medicaid services  
500 cohort. *Circulation*. 2012;126(18):2190-9.
- 501 45. Xiang D, Liu Y, Zhou S, Zhou E, Wang Y. Protective Effects of Estrogen on  
502 Cardiovascular Disease Mediated by Oxidative Stress. *Oxid Med Cell Longev*.  
503 2021;2021:5523516.
- 504 46. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et  
505 al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of  
506 Early Prevention: A Scientific Statement From the American Heart Association.

- 507 Circulation. 2020;142(25):e506-e32.
- 508 47. Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, et al.  
509 Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis.  
510 2019;6(2).
- 511 48. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM.  
512 Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with  
513 acute myocardial infarction: results from the Cooperative Cardiovascular Project.  
514 Stroke. 2000;31(8):1802-11.
- 515 49. Roy-O'Reilly M, McCullough LD. Age and Sex Are Critical Factors in Ischemic  
516 Stroke Pathology. Endocrinology. 2018;159(8):3120-31.
- 517 50. Yip HK, Wu CJ, Chang HW, Wang CP, Cheng CI, Chua S, et al. Cardiac rupture  
518 complicating acute myocardial infarction in the direct percutaneous coronary  
519 intervention reperfusion era. Chest. 2003;124(2):565-71.
- 520 51. Kumar S, McDaniel M, Samady H, Forouzandeh F. Contemporary  
521 Revascularization Dilemmas in Older Adults. J Am Heart Assoc. 2020;9(3):e014477.
- 522 52. Asrar Ul Haq M, Tsay IM, Dinh DT, Brennan A, Clark D, Cox N, et al. Prevalence  
523 and outcomes of trans-radial access for percutaneous coronary intervention in  
524 contemporary practise. Int J Cardiol. 2016;221:264-8.
- 525 53. Chen L, Huang Z, Lu J, Yang Y, Pan Y, Bao K, et al. Impact of the Malnutrition  
526 on Mortality in Elderly Patients Undergoing Percutaneous Coronary Intervention. Clin  
527 Interv Aging. 2021;16:1347-56.
- 528 54. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, et al.


529 Frailty: emergence and consequences in women aged 65 and older in the Women's  
530 Health Initiative Observational Study. *J Am Geriatr Soc.* 2005;53(8):1321-30.  
531 55. Saunders-Hastings P, Heong SW, Srichaikul J, Wong HL, Shoaibi A, Chada K, et  
532 al. Acute myocardial infarction: Development and application of an ICD-10-CM-based  
533 algorithm to a large U.S. healthcare claims-based database. *PLoS One.*  
534 2021;16(7):e0253580.  
535 56. Krittanawong C, Yue B. The Difficulty in Identifying Pregnancy-Associated  
536 Coronary Artery Dissection Using Nationwide Inpatient Databases. *J Am Coll Cardiol.*  
537 2018;71(4):468.  
538

## 539 **Supporting information**

540 **S1 Table. International Classification of Diseases, 10th Revision, Clinical**  
541 **Modification/Procedure Coding System (ICD-10 CM/PCS) Codes.**  
542 **S2 Table. 31 AHRQ Elixhauser comorbidity measures.**  
543 **S3 Table. Matching variables in propensity score analysis.**  
544 **S4 Table: Baseline characteristics of female versus male patients in the cohort**  
545 **after propensity score matching.**  
546



Figure



Figure